These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8748063)

  • 21. Satiety induced by endogenous and exogenous cholecystokinin is mediated by CCK-A receptors in mice.
    Weatherford SC; Chiruzzo FY; Laughton WB
    Am J Physiol; 1992 Apr; 262(4 Pt 2):R574-8. PubMed ID: 1566921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological actions of cholecystokinin.
    Crawley JN; Corwin RL
    Peptides; 1994; 15(4):731-55. PubMed ID: 7937354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview. Cholecystokinin and eating.
    Beglinger C
    Curr Opin Investig Drugs; 2002 Apr; 3(4):587-8. PubMed ID: 12090729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations.
    Kõks S; Männistö PT; Bourin M; Shlik J; Vasar V; Vasar E
    J Psychiatry Neurosci; 2000 Jan; 25(1):33-42. PubMed ID: 10721682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of cholecystokinin and opioid peptides in control of food intake.
    Baile CA; McLaughlin CL; Della-Fera MA
    Physiol Rev; 1986 Jan; 66(1):172-234. PubMed ID: 2868468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cholecystokinin in the induction of aggressive behavior: a focus on the available experimental data (review).
    Katsouni E; Zarros A; Skandali N; Tsakiris S; Lappas D
    Acta Physiol Hung; 2013 Dec; 100(4):361-77. PubMed ID: 24317345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholecystokinin in the entero-insular axis.
    Okabayashi Y; Otsuki M; Baba S
    Diabetes Res Clin Pract; 1989; 7 Suppl 1():S79-85. PubMed ID: 2680370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
    Altar CA; Boyar WC
    Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical endocrinology and metabolism. Cholecystokinin.
    Rehfeld JF
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):569-86. PubMed ID: 15533776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cholecystokinins and their receptors. Functional aspects].
    Böhme GA; Blanchard JC
    Therapie; 1992 Nov; 47(6):541-8. PubMed ID: 1301646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL; Nesse RM
    Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous cholecystokinin reduces vocalization in isolated 10-day-old rats.
    Blass EM; Shide DJ
    Behav Neurosci; 1993 Jun; 107(3):488-92. PubMed ID: 8329138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cholecystokinin hypothesis of anxiety and panic disorder.
    Bradwejn J; Koszycki D
    Ann N Y Acad Sci; 1994 Mar; 713():273-82. PubMed ID: 8185169
    [No Abstract]   [Full Text] [Related]  

  • 34. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
    Rasmussen K
    Ann N Y Acad Sci; 1994 Mar; 713():300-11. PubMed ID: 8185172
    [No Abstract]   [Full Text] [Related]  

  • 35. Cholecystokinin-induced gastroprotection: a review of current protective mechanisms.
    West SD; Mercer DW
    Dig Dis Sci; 2004 Mar; 49(3):361-9. PubMed ID: 15139482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion.
    Hebb AL; Poulin JF; Roach SP; Zacharko RM; Drolet G
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Dec; 29(8):1225-38. PubMed ID: 16242828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.
    Rotzinger S; Vaccarino FJ
    J Psychiatry Neurosci; 2003 May; 28(3):171-81. PubMed ID: 12790157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic and chemical developments of cholecystokinin receptor ligands.
    de Tullio P; Delarge J; Pirotte B
    Expert Opin Investig Drugs; 2000 Jan; 9(1):129-46. PubMed ID: 11060666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
    Hughes J; Hunter JC; Woodruff GN
    Neuropeptides; 1991 Jul; 19 Suppl():85-9. PubMed ID: 1679213
    [No Abstract]   [Full Text] [Related]  

  • 40. Release of cholecystokinin in the central nervous system.
    Raiteri M; Paudice P; Vallebuona F
    Neurochem Int; 1993 Jun; 22(6):519-27. PubMed ID: 8513278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.